Publicaciones en colaboración con investigadores/as de McMaster University (19)

2024

  1. When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review

    Journal of the American College of Cardiology, Vol. 83, Núm. 3, pp. 444-465

2023

  1. 36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE

    Thrombosis Research, Vol. 222, pp. 31-39

  2. Sex-Related Differences in Patient Characteristics, Risk Factors, and Symptomatology in Older Adults with Pulmonary Embolism: Findings from the SERIOUS-PE Study

    Seminars in Thrombosis and Hemostasis, Vol. 49, Núm. 7, pp. 725-735

2022

  1. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

    The Lancet Oncology, Vol. 23, Núm. 7, pp. e334-e347

  2. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review

    JAMA Cardiology, Vol. 7, Núm. 7, pp. 747-759

  3. Reduced-Dose Intravenous Thrombolysis for Acute Intermediate-High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial

    Thrombosis and Haemostasis, Vol. 122, Núm. 5, pp. 857-866

  4. Sex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUtcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study

    Thrombosis Research, Vol. 214, pp. 122-131

  5. Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment

    Contemporary Clinical Trials, Vol. 115

2021

  1. Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000–18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database

    The Lancet Respiratory Medicine, Vol. 9, Núm. 1, pp. 33-42

  2. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review

    Journal of the American College of Cardiology, Vol. 77, Núm. 15, pp. 1903-1921

2020

  1. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

    Journal of the American College of Cardiology, Vol. 75, Núm. 23, pp. 2950-2973

  2. Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE

    Journal of Thrombosis and Thrombolysis, Vol. 50, Núm. 2, pp. 267-277

  3. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research

    Thrombosis and Haemostasis, Vol. 120, Núm. 7, pp. 1004-1024

2019

  1. Hemopericardium and Cardiac Tamponade as a Complication of Vena Caval Filters: Systematic Review of the Published Literature and the MAUDE Database

    Clinical and Applied Thrombosis/Hemostasis

  2. Venous Thromboembolism in Patients with Liver Cirrhosis: Findings from the RIETE (Registro Informatizado de la Enfermedad TromboEmbolica) Registry

    Seminars in Thrombosis and Hemostasis, Vol. 45, Núm. 8, pp. 793-801

2018

  1. Systematic review of efficacy and safety of retrievable inferior vena caval filters

    Thrombosis Research

  2. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism

    American Journal of Medicine, Vol. 131, Núm. 4, pp. 430-437

2017

  1. Rivaroxaban with or without aspirin in stable cardiovascular disease

    New England Journal of Medicine, Vol. 377, Núm. 14, pp. 1319-1330

2016

  1. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report

    Chest, Vol. 149, Núm. 2, pp. 315-352